after providing consent, you become a participant in the long‑term extension study for duchenne muscular dystrophy.

initial measurements are taken, including vital signs, laboratory tests, electrocardiogram (ecg), and physical examination.

functional tests such as the 10‑meter walk/run, timed rise from floor, timed 4‑stair climb, stride velocity, north star ambulatory assessment, and performance of the upper limb are performed to record your baseline status.

you receive an intravenous infusion of the assigned product, either entr‑601‑45 at a dose of 20 mg/kg (milligrams per kilogram) or entr‑601‑44 at a dose of 18 mg/kg.

the infusion is given through a vein over the time specified by the study protocol.

subsequent visits occur according to the study schedule; at each visit another intravenous infusion of the same product is administered at the same dose.

during each visit vital signs, laboratory tests, ecg, and physical examination are repeated to monitor safety.

at predefined intervals the same functional tests performed at baseline (10‑meter walk/run, timed rise from floor, timed 4‑stair climb, stride velocity, north star ambulatory assessment, performance of the upper limb) are repeated to evaluate any change.

blood samples are also taken to measure the concentration of the study drug and its metabolite.

after the final scheduled visit, all assessments are completed and the study data are collected.

you will undergo a final safety evaluation and the last functional tests before the study concludes.